Syra Health Corp. (NASDAQ: SYRA) Surges Ahead: Q1 2024 Sees 47% Revenue Growth and $3.2 Million Cash Balance

Browse By

–News Direct–

By Kenneth Adams, Benzinga

Syra Health Corp. (NASDAQ: SYRA) announced its financial results for the first quarter ended March 31, 2024.

Q1 2024 Financial Highlights

  • Revenue of $1.7 million in 1Q24 compared to $1.2 million in 1Q23.

  • Business units excluding Healthcare Workforce grew 333% and comprised 19% of total revenues in 1Q24, versus only 7% in 1Q23.

  • Population Health, driven by demand for epidemiology services, saw an increase of 212% compared to 1Q23.

  • Cash balance of $3.2 million as of March 31, 2024, and no long-term debt.

2024 Financial Outlook

The company anticipates full-year 2024 revenue of $9 to $11 million, representing growth of 64%-100% versus 2023. Due to the implementation cycle of customers, the company expects the majority of its contract revenues to be realized in the second half of 2024.

Recent Operational Highlights

  • Currently, it has active contracts in 19 states across the nation.

  • Secured a one-year renewable contract with a national healthcare organization worth $660,000 to provide Healthcare Effectiveness Data and Information Set (HEDIS) outreach and support services essential for fostering positive health outcomes and reducing costs.

  • Announced a one-year, $480,000 contract from the Indiana Department of Health to administer public health and healthcare readiness assessments.

  • Awarded a one-year $450,000 contract for epidemiology services with the Shelby County Health Department in Tennessee, with two additional one-year renewal options, bringing the total potential value of the contract to $1.35 million.

  • Secured a one-year contract with Washington D.C.s Department of Behavioral Health worth approximately $250,000. The company will conduct an epidemiological study aimed at identifying the prevalence and types of behavioral health conditions that exist among D.C. youth.

  • Won multiple healthcare workforce contracts in states including Missouri, Nebraska and Virginia.

  • Announced that it has been selected as a subcontractor for a contract awarded to Caduceus Healthcare, Inc. by the federal Department of Health and Human Services, Administration for Families and Children, Office of Refugee Resettlement, Medical Staffing and Support, valued at $75 billion. Revenues will be realized after the receipt of task orders.

  • The companys research study protocol for Syrenity, Syra Healths prevention-focused mental and behavioral health platform, was approved by Pearl Institutional Review Board. The research study will be conducted by renowned university researchers and practicing psychologists who will enroll approximately 300 people with moderate or worse depression severity.

Dr. Deepika Vuppalanchi, CEO of Syra Health, said, We are proud of our impressive growth in 2024, as our revenues in the first quarter grew 47% versus last year. As such, we are confident in our 2024 revenue guidance of $9 million to $11 million, based on contracts in hand and pending implementation. The demand for our services remains strong and we believe we are properly positioned to take advantage. We are currently doing business in 19 states, and we anticipate securing new business from both the private and public sectors. We are excited about our Population Health business unit, which grew over 200% in the first quarter, driven by strong demand for our epidemiology services. Our growth remains strong in our newest business units of Digital Health and Health Education, and we are excited that our Healthcare Workforce business unit has returned to growth in 2024. Syrenity, our mental and behavioral health platform, which is focused on prevention, also holds great promise in terms of revenue for 2024 and beyond. We believe we are at the early stages of accelerating growth, which has been made possible by recent investments in our people and our technology.

Q1 2024 Financial Results

Revenue for the quarter ended March 31, 2024, was $1.7 million, compared to the $1.2 million reported in the first quarter of 2023. Strong growth was driven by Population Health, which grew 212% year over year, and Healthcare Workforce, which grew 28% year over year. Digital Health had revenues of $92,250, compared to zero last year.

Gross profit margin in the first quarter of 2024 was 10.2%, compared to 12.4% in the first quarter of 2023. The decrease in gross margins was due to the mix shift to Healthcare Workforce.

Total operating expenses for the first quarter of 2024 were $1.6 million compared to $921,781 in the first quarter of 2023. Salaries and benefits expenses increased by 61% to support general business growth and sales. Professional fees declined 18% due to decreased legal and other professional costs as the Company completed its IPO process in the fourth quarter of 2023. Selling, general and administrative expenses increased by 87% due to increased operations. Depreciation expense was $12,545 compared to $11,763 in the first quarter of 2023, reflecting expanded office space. R&D expenses were $277,548, reflecting the development of technology-based solutions.

Net Loss for the third quarter of 2024 was $1.4 million compared to a net loss of $785,892 in the first quarter of 2023.

Adjusted EBITDA for the first quarter of 2024 was $(1.4 million) compared to $(762,710) in the first quarter of 2023.

Cash on hand on March 31, 2024, was $3.2 million.

Conference Call

Management held a conference call to discuss the fiscal year's financial results at 9:00 am ET on May 9, 2024.

A replay is available in the Investor Relations section of the company's website at

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the company has provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. The company uses this non-GAAP financial measure internally to facilitate period-to-period comparisons and analysis of its operating performance and liquidity and believes it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of its business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

Image sourced from Shutterstock

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Healths products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Companys operations and business strategy and the Companys expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Christine Drury

+1 463-345-8950

[email protected]

Company Website

View source version on

Syra Health

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Real Prime News journalist was involved in the writing and production of this article.